CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry

Journal of the Neurological Sciences

Volumn 306, Issue 1-2, 2011, Pages 49-53

  Koga, Masatoshi ^a   Kimura, Kazumi ^b   Shibazaki, Kensaku ^b   Shiokawa, Yoshiaki ^c   Nakagawara, Jyoji ^d   Furui, Eisuke ^e   Yamagami, Hiroshi ^f   Okada, Yasushi ^g   Hasegawa, Yasuhiro ^h   Kario, Kazuomi ⁱ   Okuda, Satoshi ^j   Naganuma, Masaki ^a   Nezu, Tomohisa ^a   Maeda, Koichiro ^a   Minematsu, Kazuo ^a   Toyoda, Kazunori ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Nakamura Memorial Hospital   (Japan)

^e KOHNAN HOSPITAL   (Japan)

^f KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

Acute stroke; Atrial fibrillation; Cardiovascular events; CHADS2 score; Outcome; rt PA; Thrombolysis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; WARFARIN; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGE; AGED; ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHADS2 SCORE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SINGLE DRUG DOSE; STROKE; STROKE PATIENT; ARTICLE; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79958766835     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.03.046     Document Type: Conference Paper

References (31)

1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
2. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92. (Pubitemid 39407328)
3. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008;39:1482-6.
4. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 2009;101:367-72.
5. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96. (Pubitemid 46842784)
6. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N. Survival after stroke-the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 2009;141:18-23.
7. Nakashima T, Toyoda K, Koga M, Matsuoka H, Nagatsuka K, Takada T, et al. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke. Int J Stroke 2009;4:425-31.
8. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Davalos A, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 2008;39:3316-22.
9. Kimura K, Iguchi Y, Shibazaki K, Terasawa Y, Inoue T, Uemura J, et al. Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke. Stroke 2008;39:2388-91.
10. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 2009;40:3591-5.
11. Nezu T, Koga M, Kimura K, Shiokawa Y, Nakagawara J, Furui E, et al. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry. Neurology 2010;75:555-61.
12. Shinohara Y, Yamaguchi T. Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision. Int J Stroke 2008;3:55-62.
13. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
14. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37:1810-5. (Pubitemid 44297734)
15. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010;41:461-5.
16. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al. Thrombolysis With 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010;41:1984-9.
17. Davalos A, Cendra E, Teruel J, Martinez M, Genis D. Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990;40:1865-9.
18. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156-9. (Pubitemid 24218878)
19. Weimar C, Ziegler A, Konig IR, Diener HC. Predicting functional outcome and survival after acute ischemic stroke. J Neurol 2002;249:888-95. (Pubitemid 34754227)
20. Henon H, Godefroy O, Leys D, Mounier-Vehier F, Lucas C, Rondepierre P, et al. Early predictors of death and disability after acute cerebral ischemic event. Stroke 1995;26:392-8.
21. Johnston KC, Connors Jr AF, Wagner DP, Knaus WA, Wang X, Haley Jr EC. A predictive risk model for outcomes of ischemic stroke. Stroke 2000;31:448-55. (Pubitemid 30078181)
22. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 1995;26:361-7.
23. Longstreth Jr WT, Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 2001;56:368-75. (Pubitemid 32144149)
24. Moroney JT, Bagiella E, Paik MC, Sacco RL, Desmond DW. Risk factors for early recurrence after ischemic stroke: the role of stroke syndrome and subtype. Stroke 1998;29:2118-24. (Pubitemid 28443528)
25. Adams Jr HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126-31. (Pubitemid 29329660)
26. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002;33:1315-20. (Pubitemid 34517053)
27. Loor HI, Groenier KH, Limburg M, Schuling J, Meyboom-de Jong B. Risks and causes of death in a community-based stroke population: 1 month and 3 years after stroke. Neuroepidemiology 1999;18:75-84. (Pubitemid 29095755)
28. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626-34. (Pubitemid 24129987)
29. Sellars C, Bowie L, Bagg J, Sweeney MP, Miller H, Tilston J, et al. Risk factors for chest infection in acute stroke: a prospective cohort study. Stroke 2007;38:2284-91. (Pubitemid 47457570)
30. Ding R, Logemann JA. Pneumonia in stroke patients: a retrospective study. Dysphagia 2000;15:51-7. (Pubitemid 30195594)
31. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82. (Pubitemid 46138121)